



## Carbyne Equity Partners acquires SuanNutra

Hamburg, December 11<sup>th</sup>, 2025

Carbyne Equity Partners (“Carbyne”) is pleased to announce the acquisition of SuanNutra, the nutraceutical ingredients business of Suanfarma, a portfolio company of ARCHIMED. The investment, marks Carbyne’s entry into the nutraceutical sector and aligns with its focus on building R&D-driven businesses alongside strong management teams. Further, the transaction supports Suanfarma’s renewed strategic focus on strengthening its position in the active pharmaceutical ingredients (API) market.

Following ARCHIMED’s acquisition of Suanfarma in 2021, the group laid the foundations for a clearer strategic direction for its nutraceutical activities. Among the early steps was the acquisition of Monteloeder, a branded ingredients company recognised for its clinically validated portfolio and scientific rigour. This strengthened SuanNutra’s capabilities, broadened its offering, and prepared the ground for its evolution into a fully distinct and independent business within the group.

In 2023, SuanNutra launched a comprehensive programme to build on these foundations and establish a fully independent, scalable organisation with its own strategic mandate and identity. A central element of this work was the creation of a high-calibre leadership team, led by CEO Anthony Weston and supported by board member Yoni Glickman. Working together, this leadership team has provided strategic clarity, measured ambition and disciplined execution required to move the business forward. Through their collective efforts, SuanNutra has delivered sustained growth, become a more agile and customer-centred organisation, and positioned itself strongly for its next phase of development.

Alongside the organisational and leadership development, SuanNutra has advanced a more deliberately customer-centred commercial model, enhancing service quality and reinforcing long-term client relationships. It has also strengthened ties with key partners and suppliers to support the continued and excellent growth of its EU-based subsidiary, Gonmisol, while laying the groundwork for future expansion in the United States. Taken together with SuanNutra’s broader strategic initiatives, these measures have contributed to ten consecutive quarters of revenue and gross profit growth, demonstrating the sustained momentum achieved across the business.

---

### Anthony Weston, CEO of SuanNutra, commented

“SuanNutra is the company it is today because of the commitment, expertise and character of the people who have shaped it. Across the organisation, colleagues have worked with dedication to strengthen our capabilities, refine our portfolio and build a culture that is both disciplined and ambitious. Their contribution has been central to the progress we have made and to the reputation SuanNutra now enjoys in our industry.

As we look ahead, we are genuinely excited to be partnering with Carbyne. Their sector understanding, long-term approach and alignment with our values make them an excellent partner for the next phase of our journey. Together, we will continue to build on the strong foundations already in place, broaden our reach and develop the opportunities that lie ahead for our people, our customers and our partners.”

**Dr Markus Petersen, Managing Partner at Carbyne, added:**

“SuanNutra is an impressive nutraceutical ingredients platform with meaningful opportunities ahead – whether through securing dedicated supply chains, broadening its portfolio of clinically validated ingredients or deepening its relevance among an already diverse customer base. We have great confidence in the management team and look forward to building the next chapter together.”

**Benoit Varichon, Partner at ARCHIMED, added:**

“Following the successful journeys of Natural Origin (HIS) and FYTEXIA, SuanNutra represents our third achievement in the nutraceutical space. We are proud to have supported the emergence of a truly independent leader in this fast-growing market. Carbyne’s long-standing industry insight makes them an ideal partner for SuanNutra and its management team.”

---

### **About Carbyne Equity Partners**

Carbyne Equity Partners is a private equity firm investing in growing European businesses with strong market positions and a commitment to innovation. Its focus spans nutrition, healthcare and agricultural inputs, sectors where the firm leverages its extensive network of entrepreneurial investors. Working closely with management teams, Carbyne supports businesses in accelerating growth and strengthening long-term market leadership. For more information, please visit [carbynepartners.de](https://carbynepartners.de).

### **Business and press enquiries:**

Mai Karas

+49 40 524 710 230

[mk@carbynepartners.de](mailto:mk@carbynepartners.de)

---

### **Financing Provider**

The acquisition facility was provided by Oldenburgische Landesbank (OLB) in its role as sole underwriter and lead arranger.

### **Advisory Engagements**

Carbyne Equity Partners was advised by Houlihan Lokey (financing advisory), Herbert Smith Freehills Kramer (legal due diligence, structuring, corporate and financing documentation), EY Parthenon and EY abogados Spain (financial, carve-out and tax due diligence), OC&C (commercial due diligence) and Lincoln International (M&A advisory).